Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Microbes Infect ; 11(2): 264-73, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19100857

ABSTRACT

The comprehension of the molecular mechanisms leading to Trypanosoma cruzi-elicited heart dysfunction might contribute to design novel therapeutic strategies aiming to ameliorate chronic Chagas disease cardiomyopathy. In C3H/He mice infected with the low virulence T. cruzi Colombian strain, the persistent cardiac inflammation composed mainly of CCR5(+) T lymphocytes parallels the expression of CC-chemokines in a pro-inflammatory IFN-gamma and TNF-alpha milieu. The chronic myocarditis is accompanied by increased frequency of peripheral CCR5(+)LFA-1(+) T lymphocytes. The treatment of chronically T. cruzi-infected mice with Met-RANTES, a selective CCR1/CCR5 antagonist, led to a 20-30% decrease in CD4(+) cell numbers as well as IL-10, IL-13 and TNF-alpha expression. Further, Met-RANTES administration impaired the re-compartmentalization of the activated CD4(+)CCR5(+) lymphocytes. Importantly, Met-RANTES treatment resulted in significant reduction in parasite load and fibronectin deposition in the heart tissue. Moreover, Met-RANTES treatment significantly protected T. cruzi-infected mice against connexin 43 loss in heart tissue and CK-MB level enhancement, markers of heart dysfunction. Thus, our results corroborate that therapeutic strategies based on the modulation of CCR1/CCR5-mediated cell migration and/or effector function may contribute to cardiac tissue damage limitation during chronic Chagas disease.


Subject(s)
CCR5 Receptor Antagonists , Chagas Disease/drug therapy , Chagas Disease/pathology , Chemokine CCL5/therapeutic use , Immunologic Factors/therapeutic use , Myocardium/pathology , Receptors, CCR1/antagonists & inhibitors , Trypanosoma cruzi/physiology , Animals , CD4-Positive T-Lymphocytes/immunology , Chagas Cardiomyopathy/drug therapy , Chagas Cardiomyopathy/pathology , Chemokine CCL5/pharmacology , Connexin 43/analysis , Female , Heart/parasitology , Immunologic Factors/pharmacology , Interleukin-10/biosynthesis , Interleukin-13/biosynthesis , Mice , Mice, Inbred C3H , Myocardium/chemistry , Tumor Necrosis Factor-alpha/biosynthesis
2.
Microbes Infect ; 10(6): 680-8, 2008 May.
Article in English | MEDLINE | ID: mdl-18485782

ABSTRACT

Recent reports have established an important role of CD4+CD25+ T cells in the immune regulation of infectious diseases, autoimmune disorders and cancer. In the present work, we investigated whether these cells had a regulatory role during Trypanosoma cruzi infection, using the Colombian strain. Inactivation of CD4+CD25+ cells in vivo conferred mice slightly more resistant to infection with the Colombian strain of T. cruzi, as evidenced by lower parasitemia and mortality rates. The augmented resistance to infection with Colombian strain did correlate with increased activation of effector CD4 cells. It was antibody-independent, since no difference in levels of IgM, IgG, IgG1 and IgG2a(b) recognizing T. cruzi antigens was observed throughout the infection of CD25-inactivated and control mice. Regarding pathogenesis, inflammatory infiltrate and frequency of CD4 and CD8 T cells or macrophages in the cardiac tissue was similar in both groups. Together, our data indicate that CD4+CD25+ cells have a limited role on host resistance during early T. cruzi infection. Despite exhaustive investigation, we did not observe any role for these regulatory cells in the pathogenesis of experimental chronic Chagas' disease.


Subject(s)
CD4 Antigens/analysis , Chagas Disease/immunology , T-Lymphocyte Subsets/immunology , Trypanosoma cruzi/immunology , Trypanosoma cruzi/pathogenicity , Animals , Interleukin-2 Receptor alpha Subunit/analysis , Interleukin-2 Receptor alpha Subunit/metabolism , Mice , T-Lymphocyte Subsets/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...